DaVita stock softens as investors weigh FY 2026 EPS guidance and market cap

Published on 09/19/2026 at 18:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita stock opened at USD 183.59 on September 18, 2026, with a market capitalization of about USD 11.73 billion and a 52-week range between USD 101.00 and USD 247.49. The company is guiding for FY 2026 EPS between USD 14.10 and USD 15.20, giving investors a clear earnings framework.

DVA, US23804L1035, Illustration mit AI erstellt.

DaVita Inc. stock (ISIN US23804L1035) is trading below its recent highs as investors digest fresh guidance and valuation signals for fiscal year 2026. As of September 18, 2026, the kidney-care specialist opened at USD 183.59 on the New York Stock Exchange, corresponding to a market capitalization of about USD 11.73 billion and standing well under its 52-week high of USD 247.49 while remaining comfortably above its 52-week low of USD 101.00.

Fresh FY 2026 EPS guidance frames expectations

According to MarketBeat on September 19, 2026, DaVita has set its guidance for fiscal year 2026 earnings per share in a range between USD 14.10 and USD 15.20, giving the market a relatively tight corridor for the coming year. This guidance range, which spans USD 1.10 from the low to the high end, provides a reference band against which investors can compare current valuation metrics such as the company’s price-to-earnings ratio of 15.02 reported in the same overview for the current share price context.

In the same filing commentary, MarketBeat highlights that institutional investor Corient Private Wealth LP reduced its position in DaVita by 26,571 shares, a move that underscores active portfolio management around the stock as the guidance becomes visible. The same source notes that DaVita shares opened at USD 183.59 on that recent trading day, with the market capitalization at USD 11.71 billion and the stock carrying a price-to-earnings-growth ratio of 0.47 and a beta of 0.83, figures that help investors assess the trade-off between growth, valuation and volatility.

Analyst consensus supports a moderate buy view

A key part of the current picture for DaVita stock is the analyst consensus on the shares. According to MarketBeat, four research analysts currently rate DaVita stock as a Buy and three assign a Hold rating, resulting in an overall average rating of “Moderate Buy” for the company. The same consensus overview lists an average analyst price target of USD 233.43 for DaVita shares, implying notable upside potential from the recent opening price of USD 183.59, with the targeted level sitting about USD 50 above the latest trading reference.

From an investor’s perspective, this combination of a Moderate Buy rating and a USD 233.43 average price target relative to the USD 183.59 opening quote suggests that analysts see room for performance if DaVita delivers within or above its guided EPS corridor of USD 14.10 to USD 15.20 for fiscal year 2026. The comparison between the mid-point of that EPS range, roughly USD 14.65, and the current price implies a forward price-to-earnings multiple that remains in the low double digits, which many investors may view as balanced when set against DaVita’s role in the kidney-care segment and its relatively low beta of 0.83 as highlighted in the MarketBeat data.

Market capitalization and 52-week range highlight valuation context

The latest market capitalization figures add another layer to the valuation story. As of September 18, 2026, DaVita’s market capitalization stood at approximately USD 11.73 billion, according to an overview from CompaniesMarketCap, which cites Nasdaq data for the same figure. This market cap confirms the company’s position in the mid-cap segment of the U.S. market and provides a benchmark for comparing DaVita with other healthcare and dialysis-related names.

The same MarketBeat filing summary reports that DaVita shares have a twelve-month low of USD 101.00 and a twelve-month high of USD 247.49, a span of USD 146.49 between the extremes. With the stock recently opening at USD 183.59, the price stands USD 82.59 above the 52-week low and USD 63.90 below the 52-week high, positioning the shares in the upper half of the range but still noticeably off their peak. For investors, this quantified distance to the 52-week high and low offers a concrete sense of how much of the earlier rally remains and how much downside cushion there has been over the past year.

Stock level and trading venue

DaVita stock trades on the New York Stock Exchange under the ticker DVA, giving it access to deep liquidity and visibility among U.S. healthcare investors. The reference price for the current assessment is the NYSE opening price of USD 183.59 on September 18, 2026, in U.S. dollars, which sits within the quantified twelve-month trading band between USD 101.00 and USD 247.49 mentioned in the MarketBeat data and corresponds to a market capitalization of around USD 11.71 billion for the company.